Redefining Risk of Recurrence: Latest advances with CDK4/6 inhibitors in HR+/HER2− early breast cancer

from Medical Digest & Congress Report · host Medical Congress News

Michael Gnant have been the Co-Chair of the highly successful, annual St Gallen Breast Cancer Conference in Vienna, and chaired a session about the latest advances of CDK4/6 inhibitor treatment in HR+/HER2− early breast cancer, focusing on risk of recurrence.Video: https://medicaldigest.org/scientific-contents/interview:redefining-risk-recurrence-latest-advances-cdk46-inhibitors-hrher2-early-breast-cancer

Episode metadata supplied by the publisher feed · Published Mar 21, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Redefining Risk of Recurrence: Latest advances with CDK4/6 inhibitors in HR+/HER2− early breast cancer

0:00 13:27

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 13 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on March 21, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!